{"nct_id":"NCT04143958","title":"To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease","status":"WITHDRAWN","status_verified_date":"2023-04","start_date":"2020-09","start_date_type":"ESTIMATED","primary_completion_date":"2023-11","primary_completion_date_type":"ESTIMATED","completion_date":"2023-11","completion_date_type":"ESTIMATED","phases":["PHASE4"],"tickers":["SNY"]}